Academic Journal
Metabolic reprogramming and immune regulation in acute myeloid leukemia.
| Τίτλος: | Metabolic reprogramming and immune regulation in acute myeloid leukemia. |
|---|---|
| Συγγραφείς: | Hao X; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China., Fan C; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China., Yan L; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China., Jianati R; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China., Guo Y; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China., Zhou X; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China., Zhu G; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China., Zhang Y; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China., Zheng C; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China., Zhang Y; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China., Shi Z; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China. |
| Πηγή: | Frontiers in immunology [Front Immunol] 2025 Dec 10; Vol. 16, pp. 1655005. Date of Electronic Publication: 2025 Dec 10 (Print Publication: 2025). |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [Lausanne : Frontiers Research Foundation] |
| Ιατρικοί όροι (MeSH): | Leukemia, Myeloid, Acute*/metabolism , Leukemia, Myeloid, Acute*/immunology , Leukemia, Myeloid, Acute*/therapy , Energy Metabolism* , Cellular Reprogramming* , Immunomodulation*, Tumor Microenvironment/immunology ; Immunotherapy/methods ; Metabolic Networks and Pathways/immunology ; Humans ; Animals ; Metabolic Reprogramming |
| Περίληψη: | The most prevalent kind of acute leukemia in adults is acute myeloid leukemia (AML). While some individuals have had better effectiveness due to advancements in targeted medications, recurrence after remission and inadequate treatment specificity continue to be significant therapeutic problems. By controlling essential metabolic pathways and metabolites, metabolic reprogramming, a crucial strategy for cellular adaptability to energy needs, modifies cellular metabolic rhythms. In addition to being involved in immune cell proliferation, differentiation, and effector function, this pathway is also essential for leukemogenesis and survival signaling in AML. By altering the expression of immune molecules, the release of certain metabolites (such as lactate, ROS, glutamine, etc.) has a significant impact on the immune response to tumors. It is noteworthy that the metabolic interactions between immune cells and AML cells form a distinct pattern of energy competition in the tumor microenvironment. This study examined the new approach of targeting metabolic pathways to improve immunotherapy, systematically clarified the regulatory mechanism of metabolic reprogramming between AML cells and immune cells to counteract tumor immunity, and concentrated on the synergistic effect of current therapies and metabolic interventions. These findings offered a fresh perspective on how to fully realize the potential of metabolic therapy for AML. (Copyright © 2025 Hao, Fan, Yan, Jianati, Guo, Zhou, Zhu, Zhang, Zheng, Zhang and Shi.) |
| Competing Interests: | The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| References: | Biomark Res. 2022 Nov 23;10(1):86. (PMID: 36419115) Biochim Biophys Acta Rev Cancer. 2025 Feb;1880(1):189257. (PMID: 39746457) Int J Mol Sci. 2024 Oct 24;25(21):. (PMID: 39518969) Mol Cancer. 2021 Feb 5;20(1):28. (PMID: 33546704) Cancer Cell. 2011 Nov 15;20(5):674-88. (PMID: 22094260) Blood. 2023 Jan 19;141(3):244-259. (PMID: 36206490) Neoplasia. 2018 Oct;20(10):1008-1022. (PMID: 30189359) Small. 2024 Oct;20(42):e2403409. (PMID: 38934349) Cancers (Basel). 2024 Mar 16;16(6):. (PMID: 38539506) Blood Adv. 2024 Aug 13;8(15):4209-4220. (PMID: 38640348) Mol Cancer. 2025 Jan 8;24(1):5. (PMID: 39780248) Int Immunopharmacol. 2023 Dec;125(Pt B):111211. (PMID: 37956488) Cell Metab. 2022 Sep 6;34(9):1312-1324.e6. (PMID: 36007522) Med Oncol. 2020 Jul 28;37(8):72. (PMID: 32725458) Am J Cancer Res. 2021 Nov 15;11(11):5726-5742. (PMID: 34873490) Blood Cancer J. 2024 Jan 23;14(1):15. (PMID: 38253683) Blood Adv. 2024 Apr 9;8(7):1747-1759. (PMID: 38324726) Nat Cell Biol. 2022 Nov;24(11):1574-1583. (PMID: 36229606) Front Immunol. 2021 Dec 17;12:730970. (PMID: 34975835) Int J Mol Sci. 2024 Aug 23;25(17):. (PMID: 39273126) Sci Adv. 2023 Apr 14;9(15):eadf8522. (PMID: 37058562) Clin Cancer Res. 2021 Dec 1;27(23):6514-6528. (PMID: 34479957) Cancer Immunol Immunother. 2011 Dec;60(12):1669-81. (PMID: 21989580) J Transl Med. 2024 Nov 6;22(1):1002. (PMID: 39506790) Blood. 2019 Dec 12;134(24):2183-2194. (PMID: 31697807) Transplant Cell Ther. 2023 Aug;29(8):510.e1-510.e9. (PMID: 37169289) Semin Hematol. 2024 Dec;61(6):470-478. (PMID: 39603905) Antioxid Redox Signal. 2024 Aug;41(4-6):322-341. (PMID: 38445392) Signal Transduct Target Ther. 2023 Sep 30;8(1):391. (PMID: 37777506) Cell Commun Signal. 2024 Aug 7;22(1):391. (PMID: 39113090) Cell Res. 2020 Aug;30(8):649-659. (PMID: 32709897) Front Immunol. 2021 Oct 12;12:757836. (PMID: 34712243) Cell Stem Cell. 2016 Jul 7;19(1):23-37. (PMID: 27374788) Nature. 2017 May 25;545(7655):500-504. (PMID: 28514443) Haematologica. 2024 Aug 01;109(8):2500-2514. (PMID: 38235501) Blood Adv. 2023 Dec 26;7(24):7525-7538. (PMID: 37639313) JAMA Oncol. 2024 Oct 1;10(10):1417-1425. (PMID: 39115831) J Exp Med. 2023 Jun 5;220(6):. (PMID: 36995340) Annu Rev Immunol. 2021 Apr 26;39:667-693. (PMID: 33637018) Eur J Med Chem. 2024 Apr 5;269:116352. (PMID: 38537512) Mol Ther. 2024 Jul 3;32(7):2393-2405. (PMID: 38720457) bioRxiv. 2025 Mar 06;:. (PMID: 39185193) FEBS J. 2023 Feb;290(3):584-599. (PMID: 34822226) Haematologica. 2022 Nov 01;107(11):2562-2575. (PMID: 35172562) J Hematol Oncol. 2021 Apr 26;14(1):70. (PMID: 33902674) Cell. 2023 Jul 20;186(15):3148-3165.e20. (PMID: 37413990) JCI Insight. 2023 Oct 9;8(19):. (PMID: 37665633) Nat Rev Cancer. 2016 Nov;16(11):680-693. (PMID: 27658530) J Extracell Vesicles. 2021 Nov;10(13):e12168. (PMID: 34807526) Front Immunol. 2023 May 09;14:1112059. (PMID: 37228595) Acta Pharm Sin B. 2023 Jul;13(7):3027-3042. (PMID: 37521858) Front Cell Dev Biol. 2022 Sep 23;10:990034. (PMID: 36211454) Nat Metab. 2023 Nov;5(11):1840-1843. (PMID: 37990075) Blood. 2019 Sep 26;134(13):1014-1023. (PMID: 31416801) Blood Rev. 2021 Jul;48:100786. (PMID: 33353770) Cancer Cell Int. 2024 Oct 27;24(1):354. (PMID: 39465367) Cancer Lett. 2022 Jun 1;535:215659. (PMID: 35321842) Trends Mol Med. 2021 Apr;27(4):332-344. (PMID: 33121874) Blood Adv. 2022 Jan 11;6(1):87-99. (PMID: 34535017) Int J Mol Sci. 2023 Dec 13;24(24):. (PMID: 38139250) Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):294-302. (PMID: 31808897) Front Oncol. 2023 Nov 30;13:1302356. (PMID: 38098504) Cancer Res. 2024 Apr 1;84(7):1101-1114. (PMID: 38285895) Cancers (Basel). 2020 Apr 01;12(4):. (PMID: 32244756) Cells. 2021 Oct 09;10(10):. (PMID: 34685679) Blood Adv. 2023 Dec 26;7(24):7585-7596. (PMID: 37903311) J Immunother Cancer. 2024 Nov 21;12(11):. (PMID: 39577869) Front Immunol. 2023 Jun 29;14:1211221. (PMID: 37457701) J Hematol Oncol. 2018 Aug 2;11(1):100. (PMID: 30068361) Front Immunol. 2021 Mar 10;12:651687. (PMID: 33777052) Am J Hematol. 2025 Mar;100 Suppl 2:23-37. (PMID: 39960017) Cell Metab. 2021 Dec 7;33(12):2415-2427.e6. (PMID: 34879240) Trends Immunol. 2024 Apr;45(4):259-273. (PMID: 38503657) Expert Opin Ther Targets. 2023 Jul-Dec;27(10):939-952. (PMID: 37736880) Br J Cancer. 2020 Jan;122(1):94-101. (PMID: 31819174) Cell Commun Signal. 2023 Sep 21;21(1):252. (PMID: 37735675) Cell Metab. 2023 Sep 5;35(9):1580-1596.e9. (PMID: 37506695) Cancer Drug Resist. 2023 Aug 17;6(3):567-589. (PMID: 37842232) Mol Cancer. 2022 Aug 19;21(1):166. (PMID: 35986270) J Biol Chem. 2006 Apr 7;281(14):9030-7. (PMID: 16452478) Front Cell Dev Biol. 2021 Mar 05;9:645605. (PMID: 33763425) Exp Mol Med. 2022 May;54(5):601-612. (PMID: 35538212) Cell. 2008 May 30;133(5):775-87. (PMID: 18510923) Semin Cancer Biol. 2022 Nov;86(Pt 2):851-859. (PMID: 35122973) Cell Rep Med. 2024 Jun 18;5(6):101580. (PMID: 38776913) Nat Metab. 2022 Mar;4(3):389-403. (PMID: 35347316) Cells. 2019 Aug 24;8(9):. (PMID: 31450562) Cancers (Basel). 2023 Jan 27;15(3):. (PMID: 36765744) Front Immunol. 2024 Oct 11;15:1453886. (PMID: 39544945) Br J Haematol. 2024 Jul;205(1):30-47. (PMID: 38724457) Blood. 2023 Mar 9;141(10):1119-1135. (PMID: 36548959) Int Immunopharmacol. 2024 Mar 30;130:111765. (PMID: 38447414) Biology (Basel). 2023 May 02;12(5):. (PMID: 37237490) Biochem J. 2000 Aug 15;350 Pt 1:219-27. (PMID: 10926847) J Hematol Oncol. 2022 Aug 17;15(1):110. (PMID: 35978372) Cell Oncol (Dordr). 2023 Oct;46(5):1301-1316. (PMID: 37079187) Nat Med. 2024 Dec;30(12):3697-3708. (PMID: 39333315) Cell Biol Toxicol. 2024 Dec 21;41(1):11. (PMID: 39707066) Trends Immunol. 2015 Feb;36(2):81-91. (PMID: 25592731) Redox Biol. 2023 Feb;59:102575. (PMID: 36565644) J Hematol Oncol. 2024 May 20;17(1):34. (PMID: 38764055) Blood. 2021 Feb 4;137(5):661-677. (PMID: 33197925) Acta Pharm Sin B. 2024 Oct;14(10):4461-4477. (PMID: 39525575) EBioMedicine. 2021 Nov;73:103627. (PMID: 34656878) J Hematol Oncol. 2025 Jan 16;18(1):7. (PMID: 39819505) Nat Cell Biol. 2024 Mar;26(3):464-477. (PMID: 38321204) Cell Mol Immunol. 2023 Jun;20(6):666-679. (PMID: 37041314) Mol Cancer. 2024 May 31;23(1):116. (PMID: 38822351) Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Oct;31(5):1290-1295. (PMID: 37846674) Blood. 2025 Feb 13;145(7):657-658. (PMID: 39946155) Front Immunol. 2021 Mar 31;12:652687. (PMID: 33868291) Cancers (Basel). 2022 Feb 01;14(3):. (PMID: 35159023) Blood Cancer J. 2025 Apr 03;15(1):56. (PMID: 40180902) Cancer Med. 2024 May;13(9):e6806. (PMID: 38715546) Exp Hematol Oncol. 2024 Jul 11;13(1):67. (PMID: 38992654) Acta Pharm Sin B. 2024 Nov;14(11):4717-4737. (PMID: 39664426) Nat Cancer. 2020 Dec;1(12):1176-1187. (PMID: 33884374) Immunol Rev. 2023 Aug;317(1):137-151. (PMID: 37172120) Front Immunol. 2024 May 15;15:1386517. (PMID: 38812504) Front Immunol. 2024 Sep 20;15:1483400. (PMID: 39372401) Nat Rev Immunol. 2021 Nov;21(11):718-738. (PMID: 33981085) Blood Adv. 2023 Jul 11;7(13):3117-3127. (PMID: 36724515) Am J Hematol. 2023 Jun;98(6):881-889. (PMID: 36880836) Nat Rev Endocrinol. 2024 Dec;20(12):699-700. (PMID: 39304739) Cytokine Growth Factor Rev. 2022 Dec;68:81-92. (PMID: 36376165) Sci Immunol. 2022 Nov 25;7(77):eabm8182. (PMID: 36399539) Cancer Cell. 2023 Nov 13;41(11):1871-1891.e6. (PMID: 37802054) Physiol Rev. 2023 Jan 1;103(1):313-346. (PMID: 35981301) Sci Transl Med. 2020 Oct 28;12(567):. (PMID: 33115954) Cell Biosci. 2023 Oct 13;13(1):189. (PMID: 37828561) Cancer Cell Int. 2024 Nov 14;24(1):378. (PMID: 39543617) Antioxidants (Basel). 2021 Feb 19;10(2):. (PMID: 33669824) Cancer Lett. 2018 Oct 28;435:92-100. (PMID: 30102953) Discov Oncol. 2024 Aug 31;15(1):391. (PMID: 39215845) Blood Adv. 2024 Jan 9;8(1):56-69. (PMID: 37906522) Front Oncol. 2022 Mar 16;12:824562. (PMID: 35371979) Oncotarget. 2017 Aug 16;8(47):82803-82823. (PMID: 29137304) Int J Mol Sci. 2021 Jun 25;22(13):. (PMID: 34202238) Blood Res. 2024 Dec 18;59(1):42. (PMID: 39695001) Immunity. 2023 Mar 14;56(3):516-530.e9. (PMID: 36738738) Front Oncol. 2020 Feb 18;10:155. (PMID: 32133293) Front Oncol. 2023 Sep 07;13:1244280. (PMID: 37746249) Theranostics. 2025 Jan 1;15(3):993-1016. (PMID: 39776799) Nat Commun. 2022 Apr 19;13(1):2013. (PMID: 35440568) Blood Cancer Discov. 2024 Jul 1;5(4):234-248. (PMID: 38904305) Stem Cell Res Ther. 2025 Feb 10;16(1):60. (PMID: 39924510) Cell Death Differ. 2015 Mar;22(3):377-88. (PMID: 25257172) Mol Cell Proteomics. 2023 Mar;22(3):100503. (PMID: 36682716) Blood Adv. 2023 Aug 22;7(16):4358-4365. (PMID: 37196640) Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16663-8. (PMID: 21930917) Nutrients. 2023 Jun 01;15(11):. (PMID: 37299568) Leukemia. 2025 Feb;39(2):487-489. (PMID: 39558008) Curr Treat Options Oncol. 2023 Aug;24(8):1021-1035. (PMID: 37249801) Front Immunol. 2021 Aug 09;12:700374. (PMID: 34434191) JCO Oncol Pract. 2024 Dec;20(12):1637-1644. (PMID: 39013130) CA Cancer J Clin. 2025 Jan-Feb;75(1):46-67. (PMID: 39656142) J Cell Physiol. 2025 Jan;240(1):e70000. (PMID: 39835485) |
| Contributed Indexing: | Keywords: AML; immune regulation; metabolic reprogramming; metabolism; review |
| Entry Date(s): | Date Created: 20251226 Date Completed: 20251226 Latest Revision: 20251228 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12727915 |
| DOI: | 10.3389/fimmu.2025.1655005 |
| PMID: | 41451233 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2025.1655005 |